Investment Q&A

Q: Please provide an update on NLH many thanks.

Q: Would appreciate it if you could comment on their most recent (and record) Q2 earnings from last week.

Q: Roll-up companies can be amazing wealth compounders over time (CSU and BYD, for example). Do you have any tips on how to spot a good roll-up oriented company during the early stages of their development? Were there any specific catalysts or metrics you looked for when initiating coverage of CSU and BYD?

Two examples of roll-up companies I am looking into are PHA and NLH, which operate in the health care space. I know these two companies are probably too small for 5i to cover currently (but CSU and BYD were also small once-upon-a-time), but I am wondering what I should look out for when evaluating these two companies.

Q: First of all, thanks for the service you provide. I have found it extremely useful since becoming a member. Second, I apologize for the number of stocks covered in the question. If it is too many, please do not respond / post.
Within the last 12 months, I have purchased the above stocks strictly for growth or as momentum plays.
I would like to know which ones you would sell, either because their momentum has likely peaked, or because their share price growth prospects are poor. Please deduct as many credits as required. Thanks

Q: Hi folks, please get update on Nova Leap Health nlh/c. Seems to be growing with acquisitions in part of U.S. Is it similar to operations like cbii/c, well/t or doc/t (tele-med operations)....and how does the balance sheet/ Q results look?? Watched cbii/c run from .15 to .60 andddddd missed. Does nlh/c have similar potential. Thanks as always, jb Piedmnt QC

Q: Would appreciate it if you could comment on the latest results for Nova Leap Health. A microcap with lots of risk, however, they certainly seem to be moving in the right direction. Thanks as always.

HALIFAX, Nova Scotia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care industry, is pleased to announce the release of record financial results for the third quarter ended September 30, 2019. All amounts are in United States dollars unless otherwise specified.

Nova Leap Third Quarter of 2019

Highlights for the quarter ended September 30, 2019 included the following:

Nova Leap’s financial results for Q3 2019 are the best in the Company’s history;
Record quarterly EBITDA of $324,676 in Q3 2019 was an increase of 685% over Q3 2018 EBITDA of $41,357 and an increase of 49.2% over Q2 2019 EBITDA of $217,549;

Q: Hello,
What do you think about Nova Leap Healthcare? Company is growing by acquisitions and insiders hold over 30% in the company. Company increased revenues from $1M to $12M from 2017 to 2018.

Q: Would you consider this company a buy at this time?
Thanks,
Bob